Tempus’ xT CDx Achieves Breakthrough Designation as First ADLT for Tumor Mutation Profiling
July 2024- Tempus announced that the Centers for Medicare & Medicaid Services…
Tempus Announces the Appointment of David R. Epstein to Its Board Of Directors
February 2024- Tempus, a leader in artificial intelligence and precision medicine, announced…